FBLG vs. ORGO, ERAS, AVIR, SBTX, NLTX, KMDA, VRCA, RANI, XOMA, and URGN
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Organogenesis (ORGO), Erasca (ERAS), Atea Pharmaceuticals (AVIR), Silverback Therapeutics (SBTX), Neoleukin Therapeutics (NLTX), Kamada (KMDA), Verrica Pharmaceuticals (VRCA), Rani Therapeutics (RANI), XOMA (XOMA), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, community ranking, profitability, institutional ownership, risk, analyst recommendations and valuation.
Organogenesis received 96 more outperform votes than FibroBiologics when rated by MarketBeat users.
Organogenesis presently has a consensus target price of $4.83, suggesting a potential upside of 106.55%. Given FibroBiologics' higher probable upside, research analysts plainly believe Organogenesis is more favorable than FibroBiologics.
Organogenesis has a net margin of 1.14% compared to Organogenesis' net margin of 0.00%. FibroBiologics' return on equity of 1.81% beat Organogenesis' return on equity.
In the previous week, Organogenesis had 2 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Organogenesis and 2 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.27 beat Organogenesis' score of -0.50 indicating that Organogenesis is being referred to more favorably in the media.
Organogenesis has higher revenue and earnings than FibroBiologics.
49.6% of Organogenesis shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Organogenesis beats FibroBiologics on 12 of the 12 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
